Blood pressure (hypertension)
recommendations have been swinging back and forth for a number of
decades. It seems that the people in power at the time decide the
level and some are not considering the age and individuality, but
determine what they want only.
The American College of Physicians
(ACP) and the American Academy of Family Physicians (AAFP) jointly developed this guideline to present the evidence and provide clinical
recommendations based on the benefits and harms of higher versus
lower blood pressure targets for the treatment of hypertension in
adults age 60 years or older. The target audience for this guideline
includes all clinicians, and the target patient population includes
all adults age 60 years or older with hypertension.
Going back in history, at first we
said, don’t lower the blood pressure because you will decrease
perfusion to vital organs and cause strokes, etc. Then it was “the
lower the better” and that we should be aiming for presyncopal
blood pressures. Then the ACCORD study came and 120 mm Hg was not
clearly better than 135 mm Hg, so we said maybe “lower is not
always better.” Then the SPRINT study came along and a BP of 120
mm Hg was better for CV events and death. Hence, the confusion and
debate continues.
Since most diabetes patients do not die
from diabetes but from cardiovascular disease causing strokes and
heart attacks, we need to pay special attention in patients with
diabetes.
This paper evaluated 21 studies of
intensive blood pressure treatment. With treating BP to less than
150/90 mm Hg, nine trials had high-strength evidence that that there
was a reduction in mortality, cardiac events, and stroke.
For BP less than or equal to 140/85 mm
Hg, there were six studies that showed benefit with reductions in
cardiac events and stroke, but a non-significant reduction in deaths.
What is the takeaway message from the
two large studies, ACCORD and SPRINT? It could be that we should
treat our patients gently and to avoid hypotension. Targeting below
150/90 mm Hg is clearly beneficial. Targeting below 140/85 mm Hg has
benefits, but the law of diminishing returns kicks in at the lower
end. The good news is that it is safe.
The studies did not emphasize the
concept of measuring blood pressure outside the office to see if it
is spiking out in the real world. This will help identify the white
coat and masked hypertensive patients and may also tell us if
medications are reducing blood pressures for the full 24 hours.
These are all important issues that
could affect the outcomes of our hypertensive patients.
So there were 3 guidelines issued:
#1) ACP and AAFP recommend that
clinicians initiate treatment in adults age 60 years or older with
systolic blood pressure persistently at or above 150 mm Hg to achieve
a target systolic blood pressure of less than 150 mm Hg to reduce the
risk for mortality, stroke, and cardiac events. (Grade: strong
recommendation, high-quality evidence). ACP and AAFP recommend that
clinicians select the treatment goals for adults age 60 years or
older based on a periodic discussion of the benefits and harms of
specific blood pressure targets with the patient.
#2) ACP and AAFP recommend that
clinicians consider initiating or intensifying pharmacologic
treatment in adults age 60 years or older with a history of stroke or
transient ischemic attack to achieve a target systolic blood pressure
of less than 140 mm Hg to reduce the risk for recurrent stroke.
(Grade: weak recommendation, moderate-quality evidence). ACP and AAFP
recommend that clinicians select the treatment goals for adults age
60 years or older based on a periodic discussion of the benefits and
harms of specific blood pressure targets with the patient.
#3) ACP and AAFP recommend that
clinicians consider initiating or intensifying pharmacologic
treatment in some adults age 60 years or older at high cardiovascular
risk, based on individualized assessment, to achieve a target
systolic blood pressure of less than 140 mm Hg to reduce the risk for
stroke or cardiac events. (Grade: weak recommendation, low-quality
evidence). ACP and AAFP recommend that clinicians select the
treatment goals for adults aged 60 years or older based on a periodic
discussion of the benefits and harms of specific blood pressure
targets with the patient.
This guideline is based on a systematic
review of published randomized, controlled trials for primary
outcomes and observational studies for harms only.